Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07527039 · ClinicalTrials.gov registry record · Phase 4

Pectoral Block in Breast Reduction for Pain Control

A Phase 4 study, sponsored by Carilion Clinic.

Recruiting
Registry status
Phase 4
Development phase
80
Enrollment target

NCT07527039 is a Phase 4 study that is actively recruiting participants, run by Carilion Clinic. The registered enrollment target is 80 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07527039, a Phase 4 study, is actively recruiting participants, sponsored by Carilion Clinic.

RECRUITING
Registry status
Phase 4
Development phase
80 participants
Enrollment target

Study Summary

A reduction mammoplasty is a commonly performed procedure for patients with symptomatic macromastia. The procedure involves removing breast parenchyma for an overall reduction in breast size and to alleviate patient symptoms, such as back/neck pain, rashes in the inframammary fold, and bra strap indentation. It is well documented in the literature that this procedure has a statistically significant reduction in patient symptoms. Postoperatively, it has been within the norm to prescribe narcotics in order to alleviate post-procedural pain. Recently, however, the research realm has advocated a non-narcotic multimodal pain control (MMPC) approach to minimize narcotic usage. Narcotic use is associated with increased costs in the healthcare system due to reported heightened pain scores for extended duration, constipation, nausea, vomiting, opiate dependence among other factors associated with increased morbidity. The goal of this study is to determine if PECs II (pectoral block type II) block alone is non-inferior to the standard multimodal pain control with narcotics for postoperative pain reduction in breast reduction.

Interventions

  • PROCEDURE Pectoral II Nerve Block
  • DRUG Post Operative Pain Relievers

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2026-04-01
Est. Completion 2028-05
Phase Phase 4

Sponsor

Carilion Clinic

45 total trials

What the Registry Record Tells You About NCT07527039

The ClinicalTrials.gov registry entry for NCT07527039 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Carilion Clinic, which has 45 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Pectoral II Nerve Block is the first listed.

NCT07527039 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT07527039 about?

NCT07527039 is a clinical study titled "Pectoral Block in Breast Reduction for Pain Control". A reduction mammoplasty is a commonly performed procedure for patients with symptomatic macromastia. The procedure involves removing breast parenchyma for an overall reduction in breast size and to alleviate patient symptoms, such as back/neck pain, rashes in the inframammary fold, and bra strap ind...

What is the current status of trial NCT07527039?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2026-04-01. Estimated completion is 2028-05.

What interventions are being tested in trial NCT07527039?

The interventions under investigation include: Pectoral II Nerve Block (PROCEDURE), Post Operative Pain Relievers (DRUG).

Who is sponsoring clinical trial NCT07527039?

This trial is sponsored by Carilion Clinic, which has 45 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.